Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR)
- 21 October 2012
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 38 (08), 905-907
- https://doi.org/10.1055/s-0032-1328890
Abstract
The U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS), familiarly known as “MedWatch,” is the nation's primary tool for postmarket pharmaceutical safety surveillance. This system relies on adverse events voluntarily reported by health care providers and consumers either directly to the FDA or to drug manufacturers, which are required to prepare and forward the information to the agency. Little is known about how frequently adverse events are reported. Previous estimates range from 1 to 31% depending on the event, drug, and time period. We used published incidence studies to calculate reporting rates for hemorrhage, emergency hospitalization, and venous thromboembolism (VTE) associated with four drugs. We estimated annual reporting rates of 1.07% for 33,171 emergency hospitalizations of patients older than 65 years associated with warfarin, 0.9% for 13,363 hospitalizations of clopidogrel and ticlopidine, and 1.02% for an estimated 67,200 hemorrhage cases associated with warfarin. We also estimated a 9-year reporting rate of 2.3% for VTE associated with thalidomide. The incidence of these hematologic adverse drug events is high and reporting rates are low, and near the lower boundary of the 1 to 15% range seen for other events.Keywords
This publication has 8 references indexed in Scilit:
- A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actions—A SONAR ReportJournal of Oncology Practice, 2012
- Emergency Hospitalizations for Adverse Drug Events in Older AmericansThe New England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Estimating the extent of reporting to FDA: a case study of statin‐associated rhabdomyolysisPharmacoepidemiology and Drug Safety, 2008
- Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With CancerJAMA, 2006
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- Hospitalizations With Adverse Events Caused by Digitalis Therapy Among Elderly Medicare BeneficiariesArchives of Internal Medicine, 1994
- Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problemsJAMA, 1993